Mirum Pharmaceuticals, Inc. MIRM
We take great care to ensure that the data presented and summarized in this overview for Mirum Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIRM
View all-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$485 Million21.07% of portfolio
-
Janus Henderson Group PLC London, X05MShares$357 Million0.18% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$231 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.55MShares$182 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.52MShares$180 Million3.41% of portfolio
-
Bvf Inc San Francisco, CA1.5MShares$107 Million5.93% of portfolio
-
State Street Corp Boston, MA1.35MShares$96.2 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.28MShares$91.7 Million0.01% of portfolio
-
Novo Holdings Hellerup, G71.26MShares$90.3 Million7.5% of portfolio
-
Tang Capital Management LLC San Diego, CA1.24MShares$88.3 Million4.12% of portfolio
Latest Institutional Activity in MIRM
Top Purchases
Top Sells
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Insider Transactions at MIRM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Indirect |
21,070
-10.1%
|
-
|
|
Dec 22
2025
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$400,000
$80.0 P/Share
|
|
Dec 22
2025
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$115,000
$23.51 P/Share
|
|
Dec 19
2025
|
Michael G Grey |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$3,900,000
$78.0 P/Share
|
|
Dec 19
2025
|
Michael G Grey |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$100,000
$2.94 P/Share
|
|
Dec 18
2025
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
2,000
-75.0%
|
$138,000
$69.73 P/Share
|
|
Dec 18
2025
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$46,000
$23.51 P/Share
|
|
Dec 01
2025
|
Michael G Grey |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$3,700,000
$74.0 P/Share
|
|
Dec 01
2025
|
Michael G Grey |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$100,000
$2.94 P/Share
|
|
Nov 21
2025
|
Michael G Grey |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$3,500,000
$70.0 P/Share
|
|
Nov 21
2025
|
Michael G Grey |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+50.0%
|
$100,000
$2.94 P/Share
|
|
Nov 18
2025
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,133
+10.8%
|
$363,527
$19.24 P/Share
|
|
Sep 12
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,578
-19.34%
|
$727,928
$76.01 P/Share
|
|
Sep 11
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
18,333
+27.02%
|
-
|
|
Sep 11
2025
|
Laura Brege |
SELL
Open market or private sale
|
Direct |
17,000
-28.05%
|
$1,258,000
$74.7 P/Share
|
|
Sep 11
2025
|
Laura Brege |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+34.2%
|
$255,000
$15.0 P/Share
|
|
Sep 08
2025
|
Saira Ramasastry |
SELL
Open market or private sale
|
Direct |
17,000
-100.0%
|
-
|
|
Sep 08
2025
|
Saira Ramasastry |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+50.0%
|
$391,000
$23.51 P/Share
|
|
Aug 12
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,954
+8.65%
|
$76,804
$26.49 P/Share
|
|
Aug 11
2025
|
Eric Bjerkholt CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-22.08%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 559K shares |
|---|---|
| Open market or private purchase | 6.36K shares |
| Open market or private sale | 492K shares |
|---|---|
| Bona fide gift | 21.1K shares |